| __timestamp | Halozyme Therapeutics, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 205018000 |
| Thursday, January 1, 2015 | 29245000 | 392709000 |
| Friday, January 1, 2016 | 33206000 | 299694000 |
| Sunday, January 1, 2017 | 31152000 | 397061000 |
| Monday, January 1, 2018 | 10136000 | 434100000 |
| Tuesday, January 1, 2019 | 45546000 | 782200000 |
| Wednesday, January 1, 2020 | 43367000 | 1119900000 |
| Friday, January 1, 2021 | 81413000 | 2437500000 |
| Saturday, January 1, 2022 | 139304000 | 1560400000 |
| Sunday, January 1, 2023 | 192361000 | 1815800000 |
| Monday, January 1, 2024 | 159417000 | 1970500000 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of biotechnology, understanding cost structures is pivotal. Regeneron Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc. have shown intriguing trends in their cost of revenue from 2014 to 2023. Over this period, Regeneron consistently outpaced Halozyme, with its cost of revenue peaking at approximately $2.44 billion in 2021, a staggering 1,100% increase from 2014. Meanwhile, Halozyme's expenses grew by nearly 750%, reaching around $192 million in 2023. This disparity highlights Regeneron's expansive operational scale compared to Halozyme. The data suggests a strategic focus on scaling operations, particularly evident in Regeneron's 2020 surge, coinciding with increased demand for biopharmaceuticals. As the industry continues to innovate, these insights offer a glimpse into the financial strategies shaping the future of biotech.
Cost Insights: Breaking Down Amgen Inc. and Regeneron Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Walgreens Boots Alliance, Inc.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Corcept Therapeutics Incorporated's Expenses
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Alkermes plc
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs MorphoSys AG
Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Geron Corporation
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Evotec SE's Expenses
Cost of Revenue Comparison: GSK plc vs Halozyme Therapeutics, Inc.
Cost of Revenue: Key Insights for Walgreens Boots Alliance, Inc. and Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. vs Ionis Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and Geron Corporation